With more than 1.9 billion adults in the world overweight and 600 million obese adults, it is important to develop safe and effective long-term treatments for weight loss. In the United States, there are five main weight loss drugs approved by the FDA, namely orlistat, lorcaserin, naltrexone-bupropion, fentanyl topiramate and liraglutide, among which, liraglutide It is a new type of weight loss drug that has been launched in recent years, and the research on the comparison of the effect and side effects of weight loss drugs has received more and more attention.

Body fat increases with age around age 70. Beyond age 60, the risks of bariatric surgery outweigh the benefits, and with an increasing number of older adults with type 2 diabetes, liraglutide is an important tool for promoting and maintaining weight loss. a safer solution. A randomized controlled trial reported in the New England Journal showed that liraglutide can significantly reduce body weight and improve metabolism in obese and overweight patients with dyslipidemia and hypertension, while liraglutide can improve glycemic control, fasting Insulin concentrations, cardiometabolic markers, and improved quality of life, among others. Because of its dual benefits of weight control and blood sugar control, the use of liraglutide is a unique treatment for obese individuals as well as those with type 2 diabetes. To study and investigate the efficacy and safety of liraglutide versus placebo for weight management in adults with overweight or obesity and type 2 diabetes.

Liraglutide side effects

Although the effect of liraglutide is better than some traditional hypoglycemic and weight loss drugs, and the weight loss effect is getting better and better as the dose increases, the occurrence of side effects increases, the most common is gastrointestinal side effects. In order to evaluate the tolerability of liraglutide-induced nausea and vomiting during weight loss, Lean MEJ et al conducted a 20-week randomized, placebo-controlled, double-blind trial. Subcutaneous injection of laglutide 1.2mg, 1.8mg, 2.4mg, 3.0mg, the tolerable group can continue to increase the dose, most events such as nausea and vomiting occurred during the dose escalation period, the symptoms were mild to moderate, and in the 3.0mg lira In the glutide group, 48% had nausea and 13% had vomiting, and the average 1-year weight loss in the 3.0 mg group was significantly greater than that of placebo and orlistat.